You have free access to this content

Cancer

Cover image for Cancer

April 2007

Volume 109, Issue 7

Pages 1215–1449

  1. Review Articles

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
      Catheter-related bloodstream infections in hematology : Time for standardized surveillance? (pages 1215–1226)

      Leon J. Worth, Monica A. Slavin, Graham V. Brown and James Black

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22527

      The rate and etiology of catheter-related bloodstream infections (CR-BSIs) are poorly monitored in the hematology population, despite significant morbidity, mortality, and healthcare expenditure. The review focuses on the issues that are critical to establish reproducible surveillance strategies in order to address the problem of CR-BSIs in the hematology population.

    2. You have free access to this content
      Current status of radiotherapy with proton and light ion beams (pages 1227–1238)

      Carlo Greco and Suzanne Wolden

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22542

      • original image

      The article reviews the available literature for various disease sites in which particle therapy has traditionally been considered to offer clinical advantages and to highlight current lines of clinical research.

  2. Original Articles

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Association between pharmaceutical involvement and outcomes in breast cancer clinical trials (pages 1239–1246)

      Jeffrey Peppercorn, Emily Blood, Eric Winer and Ann Partridge

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22528

      • original image
      • original image
      • original image

      In this analysis of published breast cancer clinical trials, the results demonstrated that most breast cancer clinical research is supported by the pharmaceutical industry, and the trials associated with industry sponsorship are more likely to report positive results than trials without pharmaceutical industry sponsorship.

    2. You have free access to this content
      Patient variables that predict atypical cytology by nipple duct lavage (pages 1247–1254)

      Zinaida I. Bushnaq, Raheela Ashfaq, A. Marilyn Leitch and David Euhus

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22538

      • original image
      • original image
      • original image

      Neither nipple aspirate fluid production nor the 5-year Gail risk category predicted lavage atypia. Limiting nipple duct lavage to fluid-producing ducts in women with a 5-year Gail risk ≥1.7% would significantly reduce the sensitivity of the nipple duct lavage test for population screening.

    3. You have free access to this content
      Feasibility and Accuracy of Sentinel Lymph Node Biopsy After Preoperative Chemotherapy in Breast Cancer Patients With Documented Axillary Metastases (pages 1255–1263)

      Jeannie Shen, Michael Z. Gilcrease, Gildy V. Babiera, Merrick I. Ross, Funda Meric-Bernstam, Barry W. Feig, Henry M. Kuerer, Ashleigh Francis, Frederick C. Ames and Kelly K. Hunt

      Version of Record online: 28 FEB 2007 | DOI: 10.1002/cncr.22540

      A relative contraindication to sentinel lymph node (SLN) biopsy after preoperative chemotherapy is the presence of axillary metastases at initial diagnosis. In this investigation, the authors observed that SLN biopsy was feasible after preoperative chemotherapy, even in patients who presented initially with cytologically proven, lymph node-positive disease. However, the false-negative rate of SLN biopsy in this group of patients was much higher than that observed in clinically lymph node-negative patients.

    4. You have free access to this content
      The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in-breast failure in patients with early-stage breast cancer treated with breast-conserving therapy (pages 1264–1272)

      Frank A. Vicini, J. Vito Antonucci, Neal Goldstein, Michelle Wallace, Larry Kestin, Daniel Krauss, Jonathan Kunzmann, Samuel Gilbert and Scott Schell

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22529

      The authors studied the clonality of ipsilateral breast tumor recurrences (IBTRs) relative to the initial invasive carcinomas by using a polymerase chain reaction loss of heterozygosity molecular comparison assays in 29 patients who received breast-conserving therapy. Molecular clonality assays provided a more reliable means of identifying patients who may benefit from aggressive systemic therapy at the time of IBTR and provided a more accurate assessment of the efficacy of various forms of local therapy.

    5. Genitourinary Disease
      You have free access to this content
      Radical prostatectomy for clinical stage T3a disease (pages 1273–1278)

      Stephen J. Freedland, Alan W. Partin, Elizabeth B. Humphreys, Leslie A. Mangold and Patrick C. Walsh

      Version of Record online: 21 FEB 2007 | DOI: 10.1002/cncr.22544

      • original image
      • original image

      The outcomes among a select cohort of 56 men with clinical stage T3a disease treated by radical prostatectomy from 1987 to 2003 were examined. After 15 years of follow-up after surgery the prostate-specific antigen (PSA)-free survival was 49%, 27% had metastasis, and only 16% had died from prostate cancer. The study suggests that radical prostatectomy may be a feasible option for select men with clinical stage T3a disease.

    6. You have free access to this content
      Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells (pages 1279–1289)

      Katsumi Shigemura, Jack L. Arbiser, Shi-Yong Sun, Majd Zayzafoon, Peter A.S. Johnstone, Masato Fujisawa, Akinobu Gotoh, Babette Weksler, Haiyen E. Zhau and Leland W.K. Chung

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22551

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Honokiol, a soluble nontoxic natural product derived from Magnolia spp., inhibited the growth of human prostate cancer cells and cells in the tumor microenvironment, and effectively induced apoptosis and inhibited tumor angiogenesis in mice. A combination of honokiol and a low dose of docetaxel blocked human prostate cancer growth in the mouse skeleton and raises the possibility that this combination of therapy may be beneficial to human prostate cancer bone metastasis.

    7. You have free access to this content
      Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality (pages 1290–1295)

      Anthony V. D'Amico, David G. McLeod, Peter R. Carroll, Jennifer Cullen and Ming-Hui Chen

      Version of Record online: 21 FEB 2007 | DOI: 10.1002/cncr.22550

      • original image
      • original image

      Despite achieving an undetectable prostate-specific antigen (uPSA) after androgen suppression therapy, men with longer times to uPSA remain at high risk for prostate cancer-specific mortality and should be considered for randomized studies evaluating immediate vs delayed chemotherapy after the achievement of the uPSA.

    8. Gynecologic Oncology
      You have free access to this content
      Association of endometrial cancer risk with a functional polymorphism (Asp327Asn) in the sex hormone-binding globulin gene (pages 1296–1302)

      Nobuhiko Kataoka, Qiuyin Cai, Wang Hong Xu, Yong-Bing Xiang, Hui Cai, Wei Zheng and Xiao Ou Shu

      Version of Record online: 21 FEB 2007 | DOI: 10.1002/cncr.22531

      The sex hormone-binding globulin gene polymorphism Asp327Asn (reference sequence 6259) has been associated with elevated blood levels of sex hormone-binding globulin, which may reduce circulating levels of estrogen and, in turn, reduce the risk of endometrial cancer. A large, population-based study was conducted to test this hypothesis, and the results indicated that the Asn allele is related to a reduced risk of endometrial cancer among postmenopausal women.

    9. You have free access to this content
      Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort (pages 1303–1311)

      James V. Lacey Jr., Michael F. Leitzmann, Shih-Chen Chang, Traci Mouw, Albert R. Hollenbeck, Arthur Schatzkin and Louise A. Brinton

      Version of Record online: 21 FEB 2007 | DOI: 10.1002/cncr.22525

      • original image

      In a large prospective study of 73,211 women in the United States, neither the use of sequential estrogen-plus-progestin regimens nor the use of continuous estrogen-plus-progestin regimens was associated with the risk of developing endometrial cancer.

    10. You have free access to this content
      Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma : Novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE) (pages 1312–1322)

      Alessandro D. Santin, Stefania Bellone, Moira Marizzoni, Michela Palmieri, Eric R. Siegel, Jesse K. McKenney, Leah Hennings, Fabrizio Comper, Elisabetta Bandiera and Sergio Pecorelli

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22536

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The Clostridium perfringens enterotoxin (CPE) receptors claudin-3 and claudin-4 are highly expressed in uterine serous papillary cancer. These receptors may offer promising targets for the use of CPE as a novel type-specific therapy against this highly aggressive and chemotherapy-resistant variant of endometrial cancer.

    11. You have free access to this content
      A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer (pages 1323–1330)

      Edwin M. Posadas, Meghan S. Liel, Virginia Kwitkowski, Lori Minasian, Andrew K. Godwin, Mahrukh M. Hussain, Virginia Espina, Bradford J. Wood, Seth M. Steinberg and Elise C. Kohn

      Version of Record online: 1 MAR 2007 | DOI: 10.1002/cncr.22545

      • original image

      Gefitinib treatment for ovarian cancer inhibited the activity of the epidermal growth factor receptor (EGFR) in >50% of the patients in this study. The modulation of EGFR activity was correlated with gefitinib toxicity, and the current results indicated that EGFR inhibition is inadequate as a sole molecular therapeutic target in ovarian cancer.

    12. Head and Neck Disease
      You have free access to this content
      Conditional survival in head and neck squamous cell carcinoma : Results from the SEER dataset 1973–1998 (pages 1331–1343)

      Clifton D. Fuller, Samuel J. Wang, Charles R. Thomas Jr., Henry T. Hoffman, Randal S. Weber and David I. Rosenthal

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22563

      • original image
      • original image
      • original image
      • original image
      • original image

      Survival statistics for patients with head and neck squamous cell carcinomas (HNSCC) are commonly calculated from the time of diagnosis. The less commonly employed conditional survival (CS) analyzes survival for patients who have survived a period of time after diagnosis. Useful prognostic information for cancer survivors is provided by CS analysis. Estimated baseline CS parameters for HNSCC were sought using large-scale cancer registry data.

    13. You have free access to this content
      A prospective study of the impact of nasopharyngeal cancer and radiotherapy on the psychosocial condition of Chinese patients (pages 1344–1354)

      Peter W. H. Lee, Tracy T. C. Kwan, Dora L. W. Kwong, Jonathan S. T. Sham, Edmond H. N. Pow, Anne S. McMillan and Gordon K. H. Au

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22539

      • original image
      • original image

      The results from this study indicated that enduring nasopharyngeal cancer and radiotherapy had both short-term and long-term psychosocial impact on patients. Good clinical practice included proactive lessening of the side effects of radiotherapy, the provision of illness-related information, and routine assessment and care of each patient's emotional well-being.

    14. Hematologic Malignancies
      You have free access to this content
      Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia (pages 1355–1359)

      Ahmed Aribi, Hagop M. Kantarjian, Elihu H. Estey, Charles A. Koller, Deborah A. Thomas, Steven M. Kornblau, Stefan H. Faderl, Nakia M. Laddie, Guillermo Garcia-Manero and Jorge E. Cortes

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22524

      All-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin all are valuable agents for the treatment of acute promyelocytic leukemia (APL). In this study, these 3 agents were combined to treat patients with refractory or recurrent APL and produced evidence of activity and adequate tolerance, suggesting that this combination may be used to treat patients with APL without resorting to chemotherapy.

    15. You have free access to this content
      High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers (pages 1360–1364)

      Feng Wang, Rui-hua Xu, Bing Han, Yan-xia Shi, Hui-yan Luo, Wen-qi Jiang, Tong-yu Lin, Hui-qiang Huang, Zhong-jun Xia and Zhong-zhen Guan

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22549

      Patients with B-cell non-Hodgkin lymphoma exhibited a high prevalence of hepatitis B virus (HBV) infection. The results of this study indicated that HBV infection is likely to increase the incidence of B-cell lymphoma, especially among young individuals.

    16. You have free access to this content
      Diagnosis and management of chronic myeloid leukemia : A survey of American and European practice patterns (pages 1365–1375)

      Hagop M. Kantarjian, Jorge Cortes, Francçois Guilhot, Andreas Hochhaus, Michele Baccarani and Lee Lokey

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22523

      • original image

      A survey of 956 US and European oncologists/hematologists suggests that chronic myeloid leukemia (CML) management practices, in terms of the timing of treatment decisions, molecular monitoring techniques, and the benefit of new tyrosine kinase inhibitors, differ from current recommendations. Identified areas of need should be targeted in future educational activities for the CML community.

    17. You have free access to this content
      Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia (pages 1376–1383)

      Anne Etienne, Benjamin Esterni, Aude Charbonnier, Marie-Joëlle Mozziconacci, Christine Arnoulet, Diane Coso, Brigitte Puig, Jean-Albert Gastaut, Dominique Maraninchi and Norbert Vey

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22537

      • original image
      • original image

      Comorbidity is an important prognostic factor that may influence achievement of complete remission in elderly patients with acute myeloid leukemia (AML). Therefore, it may be included in the prognostic staging systems used to identify patients with AML who may benefit from induction chemotherapy.

    18. Hepatobiliary Disease
      You have free access to this content
      Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) : Results of a phase II study (pages 1384–1390)

      Samy Louafi, Valérie Boige, Michel Ducreux, Luminita Bonyhay, Touraj Mansourbakht, Thierry de Baere, Amani Asnacios, Laurent Hannoun, Thierry Poynard and Julien Taïeb

      Version of Record online: 1 MAR 2007 | DOI: 10.1002/cncr.22532

      • original image

      Thirty-four patients with advanced HCC previously untreated were prospectively enrolled in this phase II trial to evaluated a bimonthly GEMOX regimen (gemcitabine 1000mg/m2 D1; oxaliplatin 100mg/m2 D2). Thirty-two patients were assessable for efficacy and 33 for toxicity. No toxic deaths occurred. Hematological grade 3-4 toxicity consisted of thrombocytopenia (27%), neutropenia (24%); grade 3.

    19. You have free access to this content
      Management of primary liver sarcomas (pages 1391–1396)

      Juürgen Weitz, David S. Klimstra, Karina Cymes, William R. Jarnagin, Michael D'Angelica, Michael P. La Quaglia, Yuman Fong, Murray F. Brennan, Leslie H. Blumgart and Ronald P. DeMatteo

      Version of Record online: 21 FEB 2007 | DOI: 10.1002/cncr.22530

      • original image
      • original image
      • original image

      Primary hepatic sarcomas are rare tumors. The treatment and outcome of 30 patients with primary sarcoma and 5 patients with carcinosarcoma of the liver are reported.

    20. Lung Disease
      You have free access to this content
      Feasibility of percutaneous radiofrequency ablation for intrathoracic malignancies : A large single-center experience (pages 1397–1405)

      Yoshifumi Sano, Susumu Kanazawa, Hideo Gobara, Takashi Mukai, Takao Hiraki, Soichiro Hase, Shinichi Toyooka, Motoi Aoe and Hiroshi Date

      Version of Record online: 21 FEB 2007 | DOI: 10.1002/cncr.22541

      • original image
      • original image

      Percutaneous radiofrequency ablation (RFA) appears to be a safe and a minimally invasive alternative with negligible mortality and slight morbidity in selected patients with unresectable intrathoracic malignancies. However, it is very important to distinguish high-risk cases, not only based on the patient's physical status but also on tumor location, before the procedure.

    21. Sarcoma
      You have free access to this content
      Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1 (pages 1406–1412)

      Andrea Ferrari, Gianni Bisogno, Alessandra Macaluso, Michela Casanova, Paolo D'Angelo, Paolo Pierani, Ilaria Zanetti, Rita Alaggio, Giovanni Cecchetto and Modesto Carli

      Version of Record online: 1 MAR 2007 | DOI: 10.1002/cncr.22533

      • original image

      Patients affected by neurofibromatosis type 1 (NF1) are at higher risk of developing soft-tissue sarcomas (STS) than the general population. The clinical findings and outcome in 43 children and adolescents with NF1 treated for STS in the Italian protocols between 1988 and 2004 are reported.

    22. Discipline

      Medical Oncology
      You have free access to this content
      Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors : Preliminary evidence of activity in small cell and neuroendocrine carcinomas (pages 1413–1419)

      Gilberto de Lima Lopes Jr., Alberto Chiappori, George Simon, Eric Haura, Dan Sullivan, Scott Antonia, Michel Langevin, Richard Lush and Caio Max Rocha-Lima

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22522

      The objective of this study was to determine the maximum tolerated doses and dose-limiting toxicities (DLT) of carboplatin in combination with gemcitabine and irinotecan. Compromise of single-agent doses of all 3 drugs was necessary because of toxicity. The dose level selected for further study was carboplatin at an area under the curve of 4 on Day 1 plus gemcitabine 800 mg/m2 and irinotecan 80 mg/m2 on Days 1 and 8. Additional studies are warranted in patients with small cell and high-grade neuroendocrine carcinomas, because objective responses were observed in this population.

  3. Review Articles

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
      Osteopenia and cancer in children and adolescents : The fragility of success (pages 1420–1431)

      Alessandra Sala and Ronald D. Barr

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22546

      • original image

      In children and adolescents, osteopenia is a common concomitance of cancer and of its treatment, which is a detriment to the attainment of normal peak bone mass and bone health in adult life. Insights on causal factors and pathogenesis provide opportunities for amelioration of a disorder that is associated with a considerable burden of contemporary and future morbidity.

  4. Original Articles

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. Discipline

      Radiation Oncology
      You have free access to this content
      Therapeutic radiation for lymphoma : Risk of malignant mesothelioma (pages 1432–1438)

      M. Jane Teta, Edmund Lau, Bonnielin K. Sceurman and Meghan E. Wagner

      Version of Record online: 21 FEB 2007 | DOI: 10.1002/cncr.22526

      Men who were survivors of Hodgkin lymphoma and men and women who were survivors of non-Hodgkin lymphoma who had received therapeutic ionizing radiation had an increased risk of developing mesothelioma. These findings, the absence of an increased risk among patients who did not receive radiotherapy, and other consistent scientific data confirmed radiotherapy as a cause of mesothelioma.

    2. Translational Research
      You have free access to this content
      Detection of circulating urothelial cancer cells in the blood using the CellSearch System (pages 1439–1445)

      Michio Naoe, Yoshio Ogawa, Jun Morita, Kei Omori, Kumiko Takeshita, Takeshi Shichijyo, Taisuke Okumura, Atsushi Igarashi, Atsushi Yanaihara, Sanju Iwamoto, Takashi Fukagai, Akira Miyazaki and Hideki Yoshida

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22543

      • original image
      • original image
      • original image
      • original image

      Detection of circulating cancer cells in the peripheral blood of patients with urothelial cancers by CellSearch Assay.

  5. Correspondence

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
    2. You have free access to this content
      Author reply (page 1447)

      Andrew J. Li, Beth Y. Karlan and James C. Pavellea

      Version of Record online: 26 FEB 2007 | DOI: 10.1002/cncr.22548

    3. You have free access to this content
    4. You have free access to this content
      Author reply (page 1449)

      Wayne Hofstetter, Jaffer Ajani and Stephen G. Swisher

      Version of Record online: 27 FEB 2007 | DOI: 10.1002/cncr.22515

SEARCH

SEARCH BY CITATION